Meanwhile, another $70 million to $80 million of the IPO proceeds is expected to fund the launch a phase 1b study of its ...

Aktis Oncology Inc. (NASDAQ:AKTS) drew strong investor demand in its Nasdaq debut, with shares trading at $22.91 as of 12:19 ...

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Vida Ventures ("Vida"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a ...

Clinical-stage biotech Aktis Oncology (AKTS), which counts Eli Lilly (LLY) among its partners, traded sharply higher after ...

Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 ...

No IPOs are currently scheduled in the week ahead, although smaller issuers may join the calendar throughout the week. Read ...

Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Cancer drug developer Aktis Oncology announced on Thursday that it has successfully priced its upsized U.S. initial public ...

Aktis Oncology, Inc. targets $200M IPO to advance radiopharmaceuticals for solid tumors. Click for more on the upcoming AKTS ...